Gold prices edge higher on raised Fed rate cut hopes
Investors in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) might take interest in recent stock transactions involving Venrock Healthcare Capital Partners (WA:CPAP) III, L.P. and associated entities. According to a recent SEC filing, Venrock acquired a total of 104,489 shares of KalVista common stock over three separate transactions in early February. The shares were purchased at prices ranging from $9.14 to $9.29, resulting in a total investment of approximately $967,144. With a current market capitalization of $458.1 million, InvestingPro data shows the stock has gained 9.45% year-to-date, while analyst price targets range from $18 to $39.
The transactions occurred on February 7, 10, and 11, with Venrock acquiring 73,649 shares, 4,137 shares, and 26,703 shares, respectively. Following these acquisitions, Venrock’s total holdings in KalVista increased to 5,117,285 shares, held indirectly through various funds.
These transactions highlight Venrock’s continued investment interest in KalVista, a pharmaceutical company based in Cambridge, Massachusetts.
In other recent news, Kalvista Pharmaceuticals has been receiving considerable attention from analysts due to its development of sebetralstat, a treatment for hereditary angioedema (HAE). JMP Securities reiterated a Market Outperform rating for Kalvista, maintaining a price target of $19, and highlighted the potential of sebetralstat to capture a significant portion of the HAE market. Similarly, TD Cowen initiated coverage of Kalvista, assigning a Buy rating and a price target of $30, based on the potential of sebetralstat to meet significant market demand.
BofA Securities also initiated coverage on Kalvista, assigning a Buy rating and a price target of $22, noting the potential for sebetralstat to achieve peak risk-adjusted sales of $604 million by 2035. In addition, Kalvista announced that it has received Orphan Drug Designation for sebetralstat from Japan’s Ministry of Health, Labour and Welfare, marking a significant advancement in HAE treatment.
These developments highlight the potential of Kalvista’s drug development pipeline and its ability to meet patient needs and grow its market share in the coming years. These are recent developments, and their potential impact on Kalvista’s performance will be closely watched by investors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.